GLP-1アゴニストと腸内微生物群:双方向的な関係
Srinivas Kamath1, Nicole S L Chan1, Paul Joyce1
1School of Pharmacy and Biomedical Science, Adelaide University, Adelaide, South Australia, Australia.
British journal of clinical pharmacology
|February 18, 2026
まとめ
グルカゴン類ペプチド-1 (GLP-1) 受容体アゴニストは腸内細菌に影響を与え,その結果,GLP-1の分泌に影響を与えます. この腸内微生物群の相互作用を理解することは,パーソナライズされた糖尿病と肥満治療の鍵です.
科学分野:
- 薬理学と代謝に関する研究
- マイクロバイオーム科学 マイクロバイオーム科学
- インクレチン生物学 インクレチン生物学
背景:
- グルカゴン類ペプチド-1 (GLP-1) 受容体アゴニストは,2型糖尿病 (T2DM) と肥満管理に不可欠です.
- GLP-1のダイナミクスと治療反応における腸内微生物の役割は,新興の研究分野です.
- 微生物の代謝物はGLP-1の分泌に影響し,GLP-1アゴニストは腸内微生物の組成を調節する.
研究 の 目的:
- GLP-1ダイナミクスの微生物群媒介による調節に関する現在の証拠をレビューする.
- GLP-1アゴニストの薬理微生物学的効果を評価する.
- 腸内微生物群とインクレチン軸のインターフェースにおける将来の研究方向性を概説する.
主な方法:
- GLP-1,腸内微生物群,および代謝結果に関する研究の文献レビュー.
- 薬物微生物学的相互作用とマルチオミックスのデータの分析.
- ホスト - 微生物 - 薬物軸の解剖のためのコンピューティングモデリングの探索.
主要な成果:
- 腸内微生物群とGLP-1シグナル伝達との双方向的な相互作用が示唆されている.
- 腸内微生物のシグネチャーは,GLP-1アゴニスト反応の変動性を予測する可能性があります.
- マイクロバイオームの構成は,インクレチン効果を超えて代謝結果に影響します.
結論:
- ホスト-微生物-薬物軸は,GLP-1アゴニストの作用を理解する上で極めて重要です.
- パーソナライズされた代謝薬は,GLP-1治療の最適化のために微生物の文脈を活用することができます.
- 将来の研究は,原因メカニズムを解明するために,食事や宿主の遺伝子などの混乱要因に対処する必要があります.
関連する概念動画
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
What is Monogastric Digestion?
76.0K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
76.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
615
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
615
Bacterial Flora of the Large Intestine
1.7K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.7K
Drugs for Treatment of Constipation-Predominant IBS
915
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
915


